307 related articles for article (PubMed ID: 17459013)
1. Reliability of self-reported willingness-to-pay and annual income in patients treated for toenail onychomycosis.
Cham PM; Chen SC; Grill JP; Jonk YC; Warshaw EM
Br J Dermatol; 2007 May; 156(5):922-8. PubMed ID: 17459013
[TBL] [Abstract][Full Text] [Related]
2. Validity of self-reported nail counts in patients with onychomycosis: A retrospective pilot analysis.
Cham PM; Chen SC; Grill JP; Warshaw EM
J Am Acad Dermatol; 2008 Jan; 58(1):136-41. PubMed ID: 17964690
[TBL] [Abstract][Full Text] [Related]
3. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriatic arthritis: a pilot study.
Hu SW; Holt EW; Husni ME; Qureshi AA
Semin Arthritis Rheum; 2010 Apr; 39(5):384-97. PubMed ID: 19095293
[TBL] [Abstract][Full Text] [Related]
4. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial.
Warshaw EM; Fett DD; Bloomfield HE; Grill JP; Nelson DB; Quintero V; Carver SM; Zielke GR; Lederle FA
J Am Acad Dermatol; 2005 Oct; 53(4):578-84. PubMed ID: 16198776
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in ONychomycosis-Concomitant Lamisil and Debridement (IRON-CLAD), an open-label, randomized trial.
Tavakkol A; Fellman S; Kianifard F
Am J Geriatr Pharmacother; 2006 Mar; 4(1):1-13. PubMed ID: 16730616
[TBL] [Abstract][Full Text] [Related]
6. Identifying factors that affect patients' willingness to pay for inhaled insulin.
Pinto SL; Holiday-Goodman M; Black CD; Lesch D
Res Social Adm Pharm; 2009 Sep; 5(3):253-61. PubMed ID: 19733826
[TBL] [Abstract][Full Text] [Related]
7. Inter-rater and test-retest reliability of three contingent valuation question formats in south-east Nigeria.
Onwujekwe O; Fox-Rushby J; Hanson K
Health Econ; 2005 May; 14(5):529-36. PubMed ID: 15386652
[TBL] [Abstract][Full Text] [Related]
8. Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspective.
Fautrel B; Clarke AE; Guillemin F; Adam V; St-Pierre Y; Panaritis T; Fortin PR; Menard HA; Donaldson C; Penrod JR
J Rheumatol; 2005 Mar; 32(3):443-53. PubMed ID: 15742435
[TBL] [Abstract][Full Text] [Related]
9. The OnyCOE-t questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis.
Potter LP; Mathias SD; Raut M; Kianifard F; Tavakkol A
Health Qual Life Outcomes; 2006 Aug; 4():50. PubMed ID: 16911778
[TBL] [Abstract][Full Text] [Related]
10. An independent comparison of terbinafine and itraconazole in the treatment of toenail onychomycosis.
Cohen AD; Medvesovsky E; Shalev R; Biton A; Chetov T; Naimer S; Shai A; Vardy DA
J Dermatolog Treat; 2003 Dec; 14(4):237-42. PubMed ID: 14660272
[TBL] [Abstract][Full Text] [Related]
11. Willingness to pay for health insurance among rural and poor persons: field evidence from seven micro health insurance units in India.
Dror DM; Radermacher R; Koren R
Health Policy; 2007 Jun; 82(1):12-27. PubMed ID: 16971017
[TBL] [Abstract][Full Text] [Related]
12. Quality-adjusted life years was a poor predictor of women's willingness to pay in acute and chronic conditions: results of a survey.
Franic DM; Pathak DS; Gafni A
J Clin Epidemiol; 2005 Mar; 58(3):291-303. PubMed ID: 15718119
[TBL] [Abstract][Full Text] [Related]
13. Willingness-to-pay for community-based insurance in Burkina Faso.
Dong H; Kouyate B; Cairns J; Mugisha F; Sauerborn R
Health Econ; 2003 Oct; 12(10):849-62. PubMed ID: 14508869
[TBL] [Abstract][Full Text] [Related]
14. Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison.
Sigurgeirsson B; Elewski BE; Rich PA; Opper C; Cai B; Nyirady J; Bakshi R
J Dermatolog Treat; 2006; 17(1):38-44. PubMed ID: 16467022
[TBL] [Abstract][Full Text] [Related]
15. Use of willingness to pay to study values for pharmacotherapies for migraine headache.
Lenert LA
Med Care; 2003 Feb; 41(2):299-308. PubMed ID: 12555057
[TBL] [Abstract][Full Text] [Related]
16. Using willingness to pay to measure family members' preferences in mental health.
Mulvaney-Day NE
J Ment Health Policy Econ; 2005 Jun; 8(2):71-81. PubMed ID: 15998979
[TBL] [Abstract][Full Text] [Related]
17. An assessment of the burden of migraine using the willingness to pay model.
Hamelsky SW; Lipton RB; Stewart WF
Cephalalgia; 2005 Feb; 25(2):87-100. PubMed ID: 15658945
[TBL] [Abstract][Full Text] [Related]
18. A comparison of various methods of collecting self-reported health outcomes data among low-income and minority patients.
Sullivan LM; Dukes KA; Harris L; Dittus RS; Greenfield S; Kaplan SH
Med Care; 1995 Apr; 33(4 Suppl):AS183-94. PubMed ID: 7723446
[TBL] [Abstract][Full Text] [Related]
19. Willingness to pay for on-demand and prophylactic treatment for severe haemophilia in Sweden.
Carlsson KS; Höjgård S; Lethagen S; Lindgren A; Berntorp E; Lindgren B
Haemophilia; 2004 Sep; 10(5):527-41. PubMed ID: 15357780
[TBL] [Abstract][Full Text] [Related]
20. Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis.
Li C; Zeliadt SB; Hall IJ; Smith JL; Ekwueme DU; Moinpour CM; Penson DF; Thompson IM; Keane TE; Ramsey SD
Value Health; 2012; 15(5):716-23. PubMed ID: 22867781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
